Black Diamond Therapeutics(BDTX) - 2023 Q2 - Quarterly Report

During the six months ended June 30, 2023, we had cash provided by financing activities of $0.1 million, consisting of proceeds from the participation in the employee stock purchase plan. During the six months ended June 30, 2022, we had cash provided by financing activities of$0.2 million consisting of proceeds from exercise of stock options and participation in the employee stock purchase plan. | --- | --- | --- | --- | --- | |--------------------------------------------------------------------|-------|- ...